Monitoring Corticosteroid Therapy in Veterinary Dermatology

By Dr. Zubair Khalid, DVM, MS, PhD · 2026-08-11

Key Takeaways

• Systemic corticosteroid therapy in veterinary dermatology necessitates a structured, proactive monitoring plan to mitigate predictable adverse effects, focusing on early detection of iatrogenic hyperadrenocorticism, infection, and HPA axis suppression.
• Baseline assessment prior to initiating therapy is critical, including a complete physical examination, CBC, biochemistry panel, urinalysis, and blood pressure measurement, with species-specific considerations for cats (e.g., glucose monitoring).
• Regular monitoring intervals (every 3-6 months on maintenance therapy) should include serial body weight, muscle condition assessment, blood pressure, and a minimum database (CBC, biochemistry, urinalysis), with more frequent checks indicated during induction, dose changes, or adverse event development.
• Key adverse effects to monitor for include polydipsia/polyuria, polyphagia, hypertension (systolic > 160 mmHg), proteinuria (quantified by urine protein:creatinine ratio), and HPA axis suppression, which can manifest as weakness during stress or surgery.
• Safe withdrawal of corticosteroids after prolonged use (> 2 weeks) requires a gradual tapering strategy to prevent hypoadrenocorticism, with ongoing monitoring for signs of adrenal insufficiency and potential dermatologic relapse.
• Documentation of all monitoring parameters, owner communication regarding warning signs, and team coordination are paramount for ensuring patient safety and effective management of corticosteroid therapy.

Corticosteroids remain a mainstay of dermatologic therapy in dogs and cats, yet their long-term use carries a predictable burden of adverse effects that can be mitigated only through deliberate, structured monitoring. This article provides a framework for the veterinary student and practitioner who must balance clinical efficacy against iatrogenic harm. It covers the pharmacologic basis for monitoring, the organ systems at risk, practical surveillance protocols, and the recognition and management of withdrawal syndromes. The focus is on dogs and cats with skin disease, and the guidance assumes a professional reader who will consult current formularies for specific dosing decisions.

Monitoring is not a passive checklist. It is a clinical discipline that begins before the first dose is administered and continues through dose reduction and discontinuation. The goals are to detect adverse effects early, to distinguish drug-related changes from progression of the underlying dermatosis, and to withdraw therapy safely when it is no longer required. The evidence base for systemic corticosteroid monitoring in veterinary dermatology is drawn largely from extrapolation of human atopic dermatitis literature and from general veterinary pharmacology references. As noted in a review of systemic treatment for adult atopic dermatitis, data on long-term safety of systemic therapies remain insufficient, and standardized international guidelines are lacking. This uncertainty obliges the clinician to adopt a conservative, individualized monitoring plan instead of relying on a universal protocol.

At a Glance

Pharmacologic Basis for Monitoring

Corticosteroids exert their therapeutic and adverse effects through glucocorticoid and mineralocorticoid receptor activation. The glucocorticoid receptor mediates anti-inflammatory actions via transrepression of proinflammatory transcription factors and transactivation of anti-inflammatory genes. The same receptor, however, drives the metabolic consequences of therapy: hepatic gluconeogenesis, peripheral insulin resistance, protein catabolism, and redistribution of adipose tissue. Mineralocorticoid activity, present to varying degrees across different corticosteroid formulations, promotes sodium and water retention with consequent hypertension.

The therapeutic index of a given corticosteroid depends on its potency, its duration of action, and the route of administration. Oral and injectable formulations produce systemic exposure, whereas topical and otic preparations can also achieve measurable systemic levels, particularly when applied to inflamed or thin skin. In feline patients, the longer half-life of certain corticosteroids and the species' unique hepatic metabolism warrant particular caution. The MSD Veterinary Manual provides species-specific pharmacologic guidance that should inform monitoring decisions, especially regarding expected duration of adrenal suppression after cessation of therapy.

Hypothalamic-Pituitary-Adrenal Axis Suppression

Chronic exogenous corticosteroid administration suppresses endogenous cortisol production through negative feedback on the hypothalamus and pituitary. The adrenal cortex atrophies when endogenous ACTH stimulation is withdrawn, and the duration of suppression depends on the dose, the potency of the drug, the frequency of administration, and the total duration of therapy. Alternate-day dosing with a short-acting corticosteroid is less suppressive than daily dosing, but even alternate-day regimens can produce measurable suppression in susceptible individuals.

The clinical consequence of HPA axis suppression is an inability to mount a stress response. An affected patient may present with weakness, collapse, or hypotension during illness, surgery, or trauma. Monitoring for HPA suppression is therefore indicated before elective procedures and before discontinuing therapy after prolonged use. The ACTH stimulation test remains the standard diagnostic tool, though baseline cortisol measurement can serve as a screening test. The decision to test should be guided by the duration and potency of the corticosteroid used, not by the presence or absence of clinical signs, because suppression is frequently subclinical.

Metabolic and Endocrine Adverse Effects

Iatrogenic hyperadrenocorticism is the most recognizable metabolic complication of corticosteroid therapy. Polydipsia, polyuria, polyphagia, panting, abdominal distension, and bilaterally symmetric alopecia may develop within weeks to months of treatment. In dogs, the onset is dose-dependent, and even topical or otic preparations can produce these signs when used chronically. In cats, the same signs occur but may be accompanied by fragile skin syndrome, a severe complication characterized by dermal tearing with minimal trauma.

Monitoring for metabolic effects requires serial measurement of body weight, assessment of muscle condition, and questioning of the owner about water intake and appetite. A biochemistry panel should include glucose, alkaline phosphatase, alanine aminotransferase, cholesterol, and triglycerides. Alkaline phosphatase elevation in dogs is a sensitive but nonspecific marker of glucocorticoid exposure, and its magnitude does not reliably predict the severity of clinical signs. Fasting hyperglycemia may indicate overt diabetes mellitus, particularly in cats, where corticosteroid-induced insulin resistance can unmask latent disease. The Davis-Thompson Foundation pathology resources offer illustrative case material on the histologic changes of steroid hepatopathy and cutaneous atrophy that can aid in recognizing these complications.

Cardiovascular and Renal Monitoring

Hypertension is a well-documented consequence of corticosteroid therapy, mediated by mineralocorticoid effects and increased vascular reactivity to catecholamines. Blood pressure measurement should be performed at baseline and at each recheck examination in cats, which are particularly prone to corticosteroid-associated hypertension. In dogs, blood pressure monitoring is indicated when therapy is prolonged or when the patient has concurrent renal disease, diabetes mellitus, or hyperadrenocorticism. Systolic pressures consistently above 160 mmHg, as defined by the American College of Veterinary Internal Medicine consensus guidelines, warrant intervention, either by dose reduction or by addition of antihypertensive therapy.

Proteinuria may develop as a consequence of glomerular hypertension and increased glomerular filtration of protein. A urinalysis should be performed at baseline and at each monitoring interval. If proteinuria is detected, a urine protein:creatinine ratio quantifies the magnitude and provides a baseline for serial comparison. Renal function, assessed by serum creatinine and symmetric dimethylarginine in cats, should be monitored concurrently, because corticosteroid-induced hypertension can accelerate progression of preexisting renal disease.

Structured Monitoring Protocols

A structured monitoring protocol converts the pharmacology of corticosteroids into a practical schedule. The protocol must be species-specific, adjusted for the individual patient, and responsive to changes in disease activity. A written plan, shared with the owner, reduces the risk of missed adverse effects and supports consistent decision-making when dose adjustments are needed.

Baseline Assessment

Before initiating systemic corticosteroid therapy, every patient requires a complete physical examination with particular attention to body weight, body condition score, muscle mass, skin thickness, and the presence of concurrent disease. Baseline blood work should include a complete blood count, serum biochemistry profile with liver enzymes and bile acids, and a urinalysis. For dogs, a urine protein-to-creatinine ratio is indicated when proteinuria is suspected or when the patient is a breed predisposed to glomerular disease. For cats, blood glucose measurement and assessment for diabetes mellitus are essential, as corticosteroid-induced hyperglycemia is a common and potentially irreversible complication.

Baseline blood pressure measurement is mandatory in both species. Hypertension may be silent and can precede overt clinical signs. The MSD Veterinary Manual provides species-specific reference ranges and guidance on blood pressure measurement technique. Where equipment is unavailable, referral for baseline assessment should be considered before starting long-term therapy.

Monitoring Schedule

The monitoring schedule below assumes stable disease and maintenance dosing. More frequent assessment is required during induction, after dose changes, or when adverse effects appear.

Adjusting the Schedule

The schedule is a framework, not a fixed rule. Patients on alternate-day therapy may require less frequent laboratory monitoring than those on daily dosing. Cats metabolize corticosteroids differently and are more prone to diabetes mellitus and skin fragility, so glucose monitoring should be more intensive in this species. The Davis-Thompson Foundation pathology resources include case material illustrating corticosteroid-induced skin fragility in cats, which can be a useful teaching reference for recognizing this complication early.

Patients with pre-existing renal disease, cardiac disease, or diabetes require closer monitoring, often monthly, because corticosteroids can destabilize these conditions. Conversely, a young, otherwise healthy dog with seasonal atopic dermatitis may need only a brief recheck at the end of the treatment course.

Clinical Response Assessment

Monitoring corticosteroid therapy is not limited to adverse effects. The primary purpose of treatment is disease control, and the dose must be titrated to the minimum effective level. Objective assessment of skin lesions and pruritus is essential.

Pruritus Scoring

Owner-assessed pruritus scores, using a visual analogue scale from 0 to 10, provide a reproducible measure of response. The owner should score the dog at the same time each day, ideally in the evening when pruritus is often worst. A reduction of 2 or more points indicates a meaningful response. The score should be recorded in the medical record at every visit, and the owner should be asked to bring their log to rechecks.

Skin Lesion Scoring

Serial photography of affected areas provides an objective record of lesion resolution. Standardize the camera position, lighting, and distance. The clinician should document the extent of erythema, excoriation, lichenification, and alopecia at each visit. A simple lesion severity score, such as mild, moderate, or severe, is sufficient for clinical decision-making, provided the same clinician performs serial assessments.

Decision Points

The decision to reduce, maintain, or discontinue corticosteroids depends on the response to therapy and the presence of adverse effects. A dog with a pruritus score of 2 out of 10 and no adverse effects may continue at the current dose. A dog with a score of 2 but with a 10 percent weight gain and elevated liver enzymes requires dose reduction. A dog with a score of 6 after 4 weeks of therapy has failed to respond adequately, and the diagnosis or treatment plan should be reconsidered.

The review of systemic treatment in adult atopic dermatitis notes that data on long-term safety of systemic therapies are insufficient and that standardized international guidelines are lacking. This uncertainty applies to veterinary dermatology as well. The clinician must therefore rely on careful individual monitoring instead of protocolized dosing.

Withdrawal and Tapering

Abrupt discontinuation of systemic corticosteroids after prolonged use can precipitate hypoadrenocorticism, a potentially life-threatening complication. The duration of therapy and the dose determine the risk. Patients treated for more than 2 to 3 weeks, or those receiving high doses, require a gradual taper.

Tapering Strategy

The taper should be individualized. A common approach is to reduce the dose by 25 to 50 percent every 1 to 2 weeks, with the final reduction being the slowest. Alternate-day therapy is often used during the final phase of the taper to allow the hypothalamic-pituitary-adrenal axis to recover. The MSD Veterinary Manual provides guidance on recognizing and managing corticosteroid withdrawal.

Monitoring During Withdrawal

During the taper, the clinician should monitor for signs of hypoadrenocorticism, including lethargy, weakness, vomiting, diarrhea, and collapse. An ACTH stimulation test can assess adrenal function once the corticosteroid has been discontinued, but the timing of this test is debated. Some authorities recommend testing 2 to 4 weeks after the last dose, while others test only if clinical signs appear. The decision should be based on the duration and dose of prior therapy.

Relapse Risk

Dermatologic signs may recur during the taper. A mild flare can be managed with topical therapy or a temporary return to the previous dose. A severe flare suggests that the underlying disease is not controlled and that alternative or adjunctive therapy should be considered. The clinician should document the reason for any dose increase and the response to it.

Documentation and Communication

Accurate medical records are essential for monitoring corticosteroid therapy. Each visit should document the current dose, the duration of therapy, the pruritus score, the lesion severity, body weight, blood pressure, and the results of any laboratory tests. The record should also note any adverse effects and the action taken.

Owner Communication

The owner should receive a written summary of the monitoring plan, including the signs of adverse effects that require immediate veterinary attention. These include increased thirst and urination, vomiting, diarrhea, lethargy, and sudden weakness. The owner should also be advised not to discontinue the medication abruptly without veterinary guidance.

Printed Educational Materials

Printed educational materials can support owner understanding and compliance. A Cochrane review of printed educational materials found that their effect on professional practice and patient outcomes is variable and often small. The materials should therefore be concise, specific to the patient, and reinforced verbally at the consultation. A one-page handout listing the monitoring schedule and warning signs is more useful than a general brochure.

Team Coordination

In a multi-veterinarian practice, the monitoring plan should be documented in the medical record and communicated at handover. The veterinary nurse or technician can perform blood pressure measurement, blood sampling, and owner education, but the veterinarian remains responsible for interpreting results and adjusting therapy. Clear delegation of tasks prevents omissions in the monitoring schedule.

Recognized Complications and Early Detection

The principal failure modes of corticosteroid therapy in dermatology are iatrogenic hyperadrenocorticism, infection, and dermatologic rebound. Each has a characteriztic temporal signature that monitoring should capture before the complication becomes irreversible.

Iatrogenic hyperadrenocorticism develops insidiously. The earliest detectable changes are behavioral: polyuria, polydipsia, and polyphagia often precede physical changes by weeks. Owners frequently attribute these to the skin disease itself or to concurrent medication. The discriminating question at each recheck is whether water intake has changed relative to the pretreatment baseline. A dog that previously consumed 40 mL/kg/day and now consumes 90 mL/kg/day has crossed a clinically meaningful threshold regardless of whether the owner volunteers the information.

Cutaneous complications require direct inspection at every visit. Glucocorticoid-induced calcinosis cutis presents as firm, sometimes ulcerated plaques, most commonly on the ventral abdomen, groin, or axillae. It is frequently mistaken for a new allergic lesion or a bacterial furunculosis. The distinguishing feature is the gritty, chalky consistency on palpation and the failure to respond to antimicrobial therapy. Demodicosis should be suspected when a previously stable patient develops new alopecia, erythema, or pustules, particularly if the pattern is asymmetric or involves the face. Deep skin scrapings are mandatory in any dermatologic patient receiving corticosteroids who deteriorates instead of improves.

Bacterial pyoderma and Malassezia dermatitis are the most common infectious complications. Both can be masked by the anti-inflammatory effect of the corticosteroid, so the clinician must actively search for them. The presence of papules, pustules, or epidermal collarettes in a patient on glucocorticoids indicates infection until proven otherwise, and cytology should be performed instead of assumed absent because the skin looks quiet.

Common Errors and Corrective Action

The most frequent error in monitoring is treating the monitoring schedule as fixed instead of responsive. A patient who is stable at 8-week intervals does not need the same interval after a dose increase or after an intercurrent illness. The corrective action is to shorten the interval after any change in dose, any new systemic sign, or any deterioration in skin status, then extend it only after stability is confirmed.

A second error is relying on owner observation alone for systemic signs. Owners under-report polydipsia because they do not measure water intake, and they over-report pruritus because they interpret any scratching as allergic activity. The corrective action is to obtain objective data at each visit: body weight, blood pressure, and a directed physical examination that includes abdominal palpation for hepatomegaly and assessment of muscle mass over the epaxial and temporal regions.

A third error is failing to distinguish between disease flare and drug adverse effect. When a patient on corticosteroids worsens, the reflexive response is to increase the dose. The correct response is to determine why the patient worsened. Infection, demodicosis, contact irritation, and poor owner compliance all produce the same clinical picture as inadequate immunosuppression. The discriminating check is cytology, skin scraping, and a direct question about medication administration. Increasing the dose in the face of undetected infection amplifies the infection while providing false reassurance.

Limitations of the Evidence

The evidence base for monitoring protocols in veterinary dermatology is largely extrapolated from human medicine and from general glucocorticoid pharmacology. The review of systemic treatment in adult atopic dermatitis notes that data on long-term safety are insufficient and that standardized international guidelines are lacking. This gap is more pronounced in veterinary medicine, where controlled trials comparing monitoring strategies are scarce. Expert opinion therefore carries substantial weight, and opinions differ on several points.

The most contested area is the role of ACTH stimulation testing in routine monitoring. Some dermatologists recommend baseline and periodic testing in any patient expected to receive glucocorticoids beyond three months. Others reserve testing for patients with clinical signs of hyperadrenocorticism, arguing that biochemical suppression does not predict clinical complications and that testing adds cost without changing management. Both positions are defensible, the clinician should choose a policy and document the rationale.

A second area of disagreement is the target for blood pressure. Some authorities treat systolic pressures above 160 mmHg as actionable, while others use 180 mmHg. The evidence does not resolve this question for dermatologic patients specifically. The practical approach is to establish a trend: a rising pressure trajectory matters more than a single reading.

Referral and Escalation

Referral to a veterinary dermatologist is warranted when the patient fails to respond to an adequate course of therapy, when the diagnosis is uncertain, when adverse effects cannot be controlled despite dose adjustment, or when the clinician is considering a second-line immunosuppressive agent. The threshold for referral should be lower in feline patients, who are more susceptible to glucocorticoid-induced diabetes mellitus and whose skin diseases are more frequently infectious or neoplastic than allergic.

Laboratory involvement is indicated when monitoring reveals unexplained hematologic or biochemical abnormalities, when iatrogenic hyperadrenocorticism is suspected and confirmation is required, or when a patient develops a suspected opportunistic infection that requires culture and sensitivity testing. The Davis-Thompson Foundation pathology resources provide diagnostic case material that can support interpretation of biopsy and cytology findings.

Regulatory reporting obligations vary by jurisdiction. The AVMA practice resources and the WOAH terrestrial animal health standards describe reporting expectations for adverse drug events and notifiable conditions, respectively. Clinicians should be aware that suspected adverse drug reactions, particularly those resulting in death or permanent disability, are reportable in many regions, and that the reporting pathway differs from the clinical record. The MSD Veterinary Manual provides species-specific guidance on recognizing and managing glucocorticoid adverse effects that supports clinical decision-making at the point of escalation.

Frequently Asked Questions

How Can I Monitor Corticosteroid Therapy When Clients Cannot Afford Serial Laboratory Testing?

Prioritize the highest-yield tests and adjust frequency. A baseline complete blood count, serum biochemistry panel, and urinalysis with culture provide the most information per cost. When repeat testing is limited, focus on urine specific gravity, urine protein-to-creatinine ratio, and blood glucose. These detect the most common and dangerous adverse effects: diabetes mellitus, proteinuria, and urinary tract infection. Physical examination findings, including skin thickness, coat quality, muscle mass, and abdominal distension, serve as low-cost surrogates for systemic glucocorticoid exposure. Document the financial limitation in the medical record and revisit the monitoring plan whenever the client's circumstances change. The MSD Veterinary Manual provides species-specific guidance on prioritizing diagnostic testing in dermatologic patients.

What Monitoring Adjustments Are Needed for Feline Patients Compared With Dogs?

Feline patients develop iatrogenic diabetes mellitus and cutaneous fragility syndrome more readily than dogs, so glucose monitoring deserves particular emphasis. Check urine glucose at home weekly and measure blood glucose if glycosuria appears. Cats also metabolise corticosteroids differently, and clinical signs of hypercortisolism, such as alopecia and thin skin, may appear before laboratory changes. Monitor body weight and muscle condition monthly. Cats receiving long-term therapy should have blood pressure measured at each visit, as systemic hypertension can develop silently. The MSD Veterinary Manual notes species-specific differences in corticosteroid sensitivity and adverse effect profiles that should inform monitoring intensity.

What Should I Do When the Ideal Monitoring Equipment Is Unavailable in My Practice?

Use validated alternatives. If an ACTH stimulation test is unavailable, a resting cortisol concentration provides useful information about HPA axis suppression. A morning cortisol below the reference interval suggests suppression, while a value in the normal range makes significant suppression less likely. If blood pressure measurement equipment is unavailable, fundic examination for hypertensive retinopathy and palpation of femoral pulses offer crude but accessible screening. Urine glucose dipsticks and urine protein dipsticks require minimal equipment and detect the most common metabolic complications. Document the limitations of available testing and refer for definitive assessment when clinical signs suggest complications that cannot be excluded with available tools. The Davis-Thompson Foundation offers pathology resources that can help interpret biopsy findings when dermatologic complications arise.

How Should I Document Corticosteroid Monitoring in the Medical Record?

Record the drug, formulation, route, dose, and frequency at every visit, along with the indication and the current phase of therapy. Document the clinical response using the same pruritus and lesion scoring tools at each recheck so trends are visible. Record all laboratory results with reference intervals and note any values outside those intervals. Document adverse effects observed or reported, the action taken, and the rationale for that action. Include the client's reported observations about their pet's drinking, urinating, appetite, and behavior. Note any discussions about risks, benefits, and monitoring plans, including the client's understanding and consent. This record supports clinical decisions and provides continuity if another clinician assumes care. The AVMA practice resources offer guidance on medical record standards and professional communication.

How Do I Explain Monitoring Requirements to a Client Who Sees the Medication as Harmless?

Frame monitoring as protection, not bureaucracy. Explain that corticosteroids control inflammation by altering immune function, and that these same effects can cause problems in other body systems. Use concrete examples: increased thirst and urination, increased susceptibility to infection, and changes in the skin itself. Explain that monitoring detects these problems early, when they are easier to manage, instead of after they become serious. Show the client the monitoring schedule and explain what each test looks for. Acknowledge that monitoring adds cost and visits, but frame it as an investment in safer therapy. The systemic treatment review for atopic dermatitis emphasizes that long-term systemic therapy requires ongoing safety assessment, a principle that applies equally in veterinary patients.

What Is the Minimum Monitoring Schedule for a Stable Patient on Long-Term Maintenance Therapy?

For a stable patient on a consistent maintenance dose, recheck every three to six months. Each recheck should include a physical examination with body weight, body condition score, skin and coat assessment, and blood pressure measurement. Laboratory testing every six months should include a complete blood count, serum biochemistry panel with glucose and liver enzymes, and urinalysis with culture. More frequent testing is warranted if the dose has recently changed, if the patient has comorbidities, or if the owner reports new clinical signs. The WOAH terrestrial animal health standards emphasize that monitoring frequency should reflect individual patient risk, a principle that applies to corticosteroid therapy as much as to infectious disease surveillance. Adjust the schedule based on findings instead of adhering rigidly to a fixed protocol.

Related Clinical & Scientific Guides

• Hypersensitivity Reactions: Types and Mechanisms
• Therapeutic Decision-Making for Respiratory Infections in Cattle
• Monitoring Fluid Therapy in Critically Ill Veterinary Patients

References and Further Reading

• Systemic Treatment of Adult Atopic Dermatitis: A Review.. 2017.
• Printed educational materials: effects on professional practice and healthcare outcomes.. 2012.
• Davis-Thompson Foundation Veterinary Pathology Resources. Davis-Thompson Foundation.
• MSD Veterinary Manual, Professional Edition. MSD Veterinary Manual.
• American Veterinary Medical Association Practice Resources. American Veterinary Medical Association.
• WOAH Terrestrial Animal Health Code. WOAH.

Related Articles

• Monitoring Analgesic Therapy in Horses: A Practical Guide
• Monitoring Antifungal Therapy in Horses: Efficacy and Safety
• Monitoring Immunosuppressive Therapy in Veterinary Patients
• Monitoring Endocrine Therapy in Veterinary Patients: Insulin and Beyond
• Monitoring Fluid Therapy in Critically Ill Veterinary Patients

This article is educational professional reference material for veterinary audiences. It is not a substitute for veterinary diagnosis, individual clinical judgment, current product labeling, or applicable regulatory requirements.